Aggressive Malignancy PDX (Avatar) and Cryopreservation Program

Overview

About this study

The purpose of this study is to assess the ability to successfully create numerous validated patient-derived xenograft (PDX) models from patient tumor specimens obtained at surgery/biopsy via the new Pathology/TRAG cryopreservation protocol, and to generate a large catalog and repertoire of previously unavailable histologically validated PDX.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Undergoing surgical resection or biopsy of an aggressive solid tumor malignancy with the HPB Division of Surgery.
  • Patients who present with a known diagnosis of the previously diagnosed tumor types.

Exclusion Criteria:

  • No patients will be excluded or included based on race or gender.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Mark Truty, M.D., M.S.

Contact us for the latest status

Contact information:

Amro Abdelrahman M.B.B.S.

(507) 293-0287

Abdelrahman.Amro@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20489393

Mayo Clinic Footer